Insulin resistance in hypertension is associated with body fat rather than blood pressure

Hypertension

Volumn 32, Issue 1, 1998, Pages 115-122

  Toft, Ingrid ^a,b   Bønaa, Kaare H ^a   Jenssen, Trond ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Body mass index; Hypertension, essential; Insulin sensitivity; Waist to hip ratio

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031925915     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.1.115     Document Type: Article

References (56)

1. Reaven GM. Insulin resistance and compensatory hyper-insulinemia: role in hypertension, dyslipidemia and coronary heart disease. Am Heart J. 1991;121:1283-1288.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
3. Juhan Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pecloris. ECAT Angina Pectoris Study Group. Arterioscler Thromb. 1993;13:1865-1873.
4. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
5. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39: 167-174.
6. Stout RW. Insulin and atheroma: 20-year perspective. Diabetes Care. 1990;13:631-654.
7. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension, obesity and glucose tolerance. J Clin Invest. 1985;75:809-817.
8. Bonora E, Zavaroni I, Alpi O, Pezzarossa A, Bruschi F, Dall'Aglio E, Guerra L, Coscelli C, Brutturini U. Relationship between blood pressure and plasma insulin in non-obese and obese non-diabetic subjects. Diabetologia. 1987;30:719-723.
9. Manicardi V, Cannellini I, Bellodi G, Coscelli C, Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinemia in obese man. J Clin Endocrinol Metab. 1986;62:1302-1304.
10. Stout RW, Bierman EL, Ross R. Effect of insulin on cultured primate arterial smooth muscle cells. Circ Res. 1975;36:319-327.
11. Trovati M, Massucco P, Anfossi G, Cavalot F, Mularoni E, Mattiello L, Rocca G, Emanuelli G. Insulin influences the renin-angiotensin-aldosterone systems in humans. Metab Clin Exp. 1989;38:501-503.
12. DeFronzo RA. The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologia. 1981;21:165-171.
13. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225.
14. Alessi MC, Juhan Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60: 491-494.
15. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16: 207-216.
16. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
17. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
18. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation to diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl. 1985;15:41-46.
19. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl. 1985;701:38-52.
20. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care. 1979;2:1154-1160.
21. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia. 1992;35:766-770.
22. Hargreaves AD, Logan RL, Elton RA, Buchanan KD, Oliver MF, Riemersma RA. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis. 1992;94:61-69.
23. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten-year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-84.
24. Hall JE, Coleman TG, Mizelle HL. Does chronic hyper-insulinemia cause hypertension? Am J Hypertens. 1989;2:171-173.
25. Leonetti F, Iozzo P, Giaccari A, Sbraccia P, Buongiorno A, Tamburrano G, Andreani D. Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J Endocrinol Invest. 1993;16:875-880.
26. Bønaa KH, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population: the Tromsø Study. Circulation. 1992;86:394-405.
27. Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromsø study. N Engl J Med. 1990;322:795-801.
28. McGuire E, Helderman J, Tobin J, Andres R, Berman M. Effect of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 1976;41:565-573.
29. Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 1981;53:618-621.
30. DeFronzo RA, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237: E214-E222.
31. Mitrakou A, Vuorinen Markkola H, Raptis G, Toft I, Mokan M, Strumph P, Pimenta W, Veneman T, Jenssen T, Bolli G, Gerich JE. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab. 1992;75:379-382.
32. DeBodo R, Steele N, Altszuler N, Dunn A, Bishop J. On the hormonal regulation of carbohydrate metabolism: studies with C14 glucose. Recent Prog Horm Res. 1963;19:445-448.
33. Jorde R, Burhol PG, Schultz TB, Waldun HL, Lygren I, Jenssen T, Myhre ES. The effect of a 34-h fast on meal-induced rises in plasma GIP, serum insulin and blood glucose in man. Scand J Gastroenterol. 1981;16: 109-112.
34. Faber OK, Binder C. C-peptide response to glucagon: a test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977;26: 605-610.
35. Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Groop L. Hyperproinsulinemia of type 2 diabetes is not present before the development of hyperglycemia. Diabetes Care. 1994;17:1307-1310.
36. Burstein M, Scholnick HR, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-595.
37. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
38. Eriksson E, Ranby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res. 1988;50: 91-101.
39. Wiman B, Mellbring G, Ranby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta. 1983;127:279-288.
40. Hansen JB, Svensson B, Zhang CL, Lyngmo V, Nordøy A. Basal plasma concentration of tissue plasminogen activator (t-PA) and the adaption to strenuous exercise in familial hypercholesterolaemia (FH). Blood Coagul Fibrinolysis. 1994;5:781-787.
41. SAS Institute Inc. SAS/STAT Guide for Personal Computers, Version 6. Cary, NC: SAS Institute; 1987.
42. Marin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, Holm G, Sjöström L, Björntorp P. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism. 1992;41:1242-1248.
43. Peiris AN, Struve MF, Kissebah AH. Relationship of body fat distribution to the metabolic clearance of insulin in premenopausal women. Int J Obes. 1987;11:581-589.
44. Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia. 1985;28: 70-75.
45. Marangou AG, Weber KM, Boston RC, Aitken PM, Heggie JC, Kirsner RL, Best JD, Alford FP. Metabolic consequences of prolonged hyperinsulinemia in humans: evidence for induction of insulin insensitivity. Diabetes. 1986;35:1383-1389.
46. Randle PJ, Garland PB, Hales CN, Newsholm EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
47. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanism of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 1994;93: 2438-2446.
48. Byrne CD, Brindle NP, Wang TW, Hales CN. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem J. 1991;280:99-104.
49. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1991;72:96-107.
50. Colberg SR, Simoneau JA, Thaete FL, Kelley DE. Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Invest. 1995;95:1846-1853.
51. Bonora E, Bonadonna RC, Del Prato S, Gulli G, Solini A, Matsuda M, DeFronzo RA. In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes. 1993;42:764-772.
52. Widèn E, Lehto L, Kanninen T, Walston J, Shuldiner A, Groop LC. Association of a polymorphism in the beta-3 adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med. 1995;333:348-351.
53. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, Balkau B. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Pans Prospective Study. Diabetologia. 1997;40:1101-1106.
54. Cambien F, Jacqueson A, Richard JL, Rosselin G, Ducimetière P. Associations between systolic blood pressure, heart rate, and postload plasma glucose and insulin. In: Eschwege E, ed. Advances in Diabetes Epidemiology. Amsterdam, Netherlands: Elsevier Biomedical Press; 1982; 189-196.
55. Ceriello A, Quatraro A, Giugliano D. Diabetes mellitus and hypertension: the possible role of hyperglycemia through oxidative stress. Diabetologia. 1993;36:265-266.
56. Winocour PH, Alberti KG. Hyperinsulinemia as a vascular risk factor, coincidence or methodological artifact. Cardiovasc Risk Factor. 1991;1: 375-385.